Filing Flows › Mirum Pharmaceuticals (MIRM) › Q3 2026 › vs Q2 2026
Mirum Pharmaceuticals (MIRM) Q3 2026 vs Q2 2026 (quarter over quarter)
Mirum Pharmaceuticals's revenue rose $9.5M (+5%) from $176M in Q2 2026 to $186M in Q3 2026. The biggest changes: Bile Acid Medicines +$4.8M (+10%); Livmarli +$4.7M (+4%).
Mirum Pharmaceuticals, Q3 2026: revenue $186M (+40% year over year), operating margin -32.2%, net loss $40.8M, operating cash flow −$4.3M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Livmarli | $133M | $129M | $4.7M | +4% |
| Bile Acid Medicines | $52.3M | $47.5M | $4.8M | +10% |
| Revenue | $186M | $176M | $9.5M | +5% |
| Other income, net | $19.5M | −$23.0M | $42.5M | — |
| Net loss | $40.8M | $67.2M | −$26.5M | -39% |
| Costs & expenses | $246M | $243M | $2.5M | +1% |
| Operating costs | $245M | $219M | $26.7M | +12% |
| Income tax | $538K | $1.7M | −$1.2M | -68% |
| Research & development | $108M | $90.5M | $17.4M | +19% |
| SG&A | $88.9M | $81.5M | $7.4M | +9% |
| Other operating costs | $48.7M | $46.8M | $1.9M | +4% |
| Operating cash sources | $44.5M | $81.8M | −$37.3M | -46% |
| Depreciation & amortization | $6.9M | $6.9M | −$47K | -0.7% |
| Share-based compensation | $33.3M | $30.6M | $2.7M | +9% |
| Cash used in operations | $4.3M | $44.3M | −$39.9M | -90% |
| Net loss absorbed | $40.8M | $67.2M | −$26.5M | -39% |
| Working capital & other | $3.7M | $14.5M | −$10.8M | -74% |
Questions
How much did Mirum Pharmaceuticals's revenue grow quarter over quarter in Q3 2026?
Mirum Pharmaceuticals's revenue rose $9.5M (+5%) from $176M in Q2 2026 to $186M in Q3 2026.
What drove Mirum Pharmaceuticals's revenue change in Q3 2026?
Bile Acid Medicines +$4.8M (+10%); Livmarli +$4.7M (+4%).